Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Decker, Thomas; Söling, Ulrike; Hahn, Antje; Maintz, Christoph; Kurbacher, Christian Martin; Vehling-Kaiser, Ursula; Sent, Dagmar; Klare, Peter; Hagen, Volker; Chiabudini, Marco; Falkenstein, Julia; Indorf, Martin; Runkel, Eva; Potthoff, Karin

doi:10.1186/s12885-020-06747-y

BMC Cancer

Article metrics
Last updated: Fri, 26 Apr 2024 0:49:55 Z

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Access & Citations

2081

Article Accesses
1

Web of Science
3

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com